JP7208931B2 - Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類 - Google Patents

Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類 Download PDF

Info

Publication number
JP7208931B2
JP7208931B2 JP2019570553A JP2019570553A JP7208931B2 JP 7208931 B2 JP7208931 B2 JP 7208931B2 JP 2019570553 A JP2019570553 A JP 2019570553A JP 2019570553 A JP2019570553 A JP 2019570553A JP 7208931 B2 JP7208931 B2 JP 7208931B2
Authority
JP
Japan
Prior art keywords
alkyl
methyl
alkoxy
cyano
triazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019570553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524166A5 (enExample
JP2020524166A (ja
Inventor
リー ストックリー マーティン
イアン ケンプ マーク
Original Assignee
ミッション セラピューティクス リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1709824.5A external-priority patent/GB201709824D0/en
Priority claimed from GBGB1803561.8A external-priority patent/GB201803561D0/en
Application filed by ミッション セラピューティクス リミティド filed Critical ミッション セラピューティクス リミティド
Publication of JP2020524166A publication Critical patent/JP2020524166A/ja
Publication of JP2020524166A5 publication Critical patent/JP2020524166A5/ja
Application granted granted Critical
Publication of JP7208931B2 publication Critical patent/JP7208931B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019570553A 2017-06-20 2018-06-19 Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類 Active JP7208931B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1709824.5 2017-06-20
GBGB1709824.5A GB201709824D0 (en) 2017-06-20 2017-06-20 Novel Compounds
GBGB1803561.8A GB201803561D0 (en) 2018-03-06 2018-03-06 Novel compounds
GB1803561.8 2018-03-06
PCT/GB2018/051691 WO2018234775A1 (en) 2017-06-20 2018-06-19 Substituted cyanopyrrolidines with activity as dub inhibitors

Publications (3)

Publication Number Publication Date
JP2020524166A JP2020524166A (ja) 2020-08-13
JP2020524166A5 JP2020524166A5 (enExample) 2021-08-05
JP7208931B2 true JP7208931B2 (ja) 2023-01-19

Family

ID=62778943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570553A Active JP7208931B2 (ja) 2017-06-20 2018-06-19 Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類

Country Status (5)

Country Link
US (1) US11059809B2 (enExample)
EP (1) EP3642196B1 (enExample)
JP (1) JP7208931B2 (enExample)
CN (1) CN110831936B (enExample)
WO (1) WO2018234775A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522267D0 (en) * 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
JP6959332B2 (ja) 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
ES2950757T3 (es) 2017-10-06 2023-10-13 Forma Therapeutics Inc Inhibición de la peptidasa específica de la ubiquitina 30
BR112020021921A2 (pt) 2018-05-17 2021-01-26 Forma Therapeutics, Inc. compostos bicíclicos fundidos úteis como inibidores de peptidase 30 específica de ubiquitina
LT3860989T (lt) 2018-10-05 2023-06-12 Forma Therapeutics, Inc. Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
EP4441044A1 (en) 2021-12-01 2024-10-09 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
WO2023149768A1 (ko) * 2022-02-07 2023-08-10 주식회사 내쉬원 탈유비퀴틴화효소 억제제를 포함하는 소포체 스트레스 관련 질환 예방 또는 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046530A1 (en) 2014-09-23 2016-03-31 Mission Therapeutics Ltd Novel compounds
WO2016156816A1 (en) 2015-03-30 2016-10-06 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1272467A4 (en) 2000-04-06 2003-05-07 Merck Frosst Canada Inc Cathepsin cysteine protease inhibitors
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
TW200922556A (en) 2007-08-20 2009-06-01 Glaxo Group Ltd Novel cathepsin C inhibitors and their use
UY31771A1 (es) 2008-04-18 2009-09-30 Inhibidores de catepsina c
AR071480A1 (es) 2008-04-18 2010-06-23 Glaxo Group Ltd Compuesto de 1- ciano -3- pirrolidinil -bencenosulfonamida composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la enfermedad pulmonar obstructiva cronica (copd )
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
RU2712220C2 (ru) 2013-07-31 2020-01-27 Мерк Патент Гмбх Пиридины, пиримидины и пиразины в качестве ингибиторов тирозинкиназы брутона и их применение
WO2015179190A1 (en) 2014-05-19 2015-11-26 Northeastern University N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof
WO2015183987A1 (en) * 2014-05-27 2015-12-03 Pharmakea, Inc. Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2017009650A1 (en) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
CN108884068B (zh) 2016-03-24 2021-02-26 特殊治疗有限公司 作为dub抑制剂的1-氰基-吡咯烷衍生物
JP6959332B2 (ja) 2016-09-27 2021-11-02 ミッション セラピューティクス リミティド Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046530A1 (en) 2014-09-23 2016-03-31 Mission Therapeutics Ltd Novel compounds
WO2016156816A1 (en) 2015-03-30 2016-10-06 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
REGISTRY （STN） [online]，Entered STN: 2015年12月8日以前，検索日：2022年5月6日，CAS 登録番号1825275-44-2, 1825162-74-0, 1825100-39-7, 1824965-48-1, 1824954-20-2, 1822197-09-0, 1822192-17-5, 1821966-42-0, 1821632-48-7
REGISTRY （STN） [online]，Entered STN: 2016年11月23日以前，検索日：2022年5月6日，CAS 登録番号2036157-82-9, 2035068-31-4, 2034720-09-5, 2034122-54-6, 2033230-60-1, 2033060-99-8, 2031766-08-0, 2031713-88-7
REGISTRY （STN） [online]，Entered STN: 2016年11月25日以前，検索日：2022年5月6日，CAS 登録番号2038023-43-5, 2037526-90-0, 2037395-21-2, 2037266-21-8, 2037206-83-8, 2037066-95-6, 2036839-59-3, 2036284-65-6
REGISTRY （STN） [online]，Entered STN: 2016年11月28日以前，検索日：2022年5月6日，CAS 登録番号2039505-25-2, 2038813-80-6, 2038703-11-4, 2037845-12-6, 2037749-99-6, 2035201-39-7
REGISTRY （STN） [online]，Entered STN:2015年12月8日，検索日：2022年5月6日，CAS 登録番号1825132-25-9
REGISTRY （STN） [online]，Entered STN:2016年11月18日以前，検索日：2022年5月6日，CAS 登録番号2034672-98-3, 2033782-12-4, 2033478-47-4, 2030606-67-6, 1940801-27-3, 1940239-55-3
REGISTRY （STN） [online]，Entered STN:2016年11月29日，検索日：2022年5月6日，CAS 登録番号2040584-70-9
REGISTRY （STN） [online]，Entered STN:2016年11月29日以前，検索日：2022年5月6日，CAS 登録番号2040592-41-2, 2040054-88-2, 2039953-48-3, 2039944-12-0, 2039826-93-0, 2038813-55-5, 2038515-36-3, 2038256-99-2

Also Published As

Publication number Publication date
EP3642196A1 (en) 2020-04-29
US11059809B2 (en) 2021-07-13
EP3642196B1 (en) 2022-08-17
US20200172519A1 (en) 2020-06-04
JP2020524166A (ja) 2020-08-13
CN110831936A (zh) 2020-02-21
CN110831936B (zh) 2023-03-28
WO2018234775A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
JP7208931B2 (ja) Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類
US11958833B2 (en) Compounds
JP6959332B2 (ja) Ｕｓｐ３０の阻害剤としての活性を有するシアノピロリジン誘導体
TWI766882B (zh) 新穎化合物類
US11084821B2 (en) Cyanopyrrolidine derivatives with activity as inhibitors of USP30
US20210002262A1 (en) Cyanopyrrolidines as usp30 inhibitors and fibrosis treatment
JP2022546717A (ja) Ｕｓｐ３０阻害剤としての活性を有する置換シアノピロリジン類
WO2021239863A1 (en) N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
MD4161929T2 (ro) 1-(5-(2-Cianopiridin-4-il)oxazol-2-carbonil)-4-metilhexahidropirolo[3,4-b]pirol-5(1H)-carbonitril în calitate de inhibitor al USP30 pentru utilizare în tratamentul disfuncției mitocondriale al cancerului și al fibrozei
CN115461340A (zh) 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物
JP2023529570A (ja) Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン
WO2022084479A1 (en) N-cyanopyrrolidines with activity as usp30 inhibitors
RU2844289C1 (ru) 1-(5-(2-Цианопиридин-4-ил)оксазол-2-карбонил)-4-метилгексагидропирроло[3,4-b]пиррол-5(1H)-карбонитрил в качестве ингибитора USP30 для применения в лечении митохондриальной дисфункции, рака и фиброза
JP2024544660A (ja) Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン
CN118302422A (zh) 具有作为usp30抑制剂的活性的取代的n-氰基吡咯烷
HK40081706A (en) N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
HK40077361A (en) N-cyanopyrrolidines with activity as usp30 inhibitors
HK1256059B (en) An inhibitor of deubiquitylating enzymes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230106

R150 Certificate of patent or registration of utility model

Ref document number: 7208931

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150